title: NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
authors.forename: Sarah
authors.initials: S
authors.lastname: Clarke
authors.forename: John
authors.initials: J
authors.lastname: O'Reilly
authors.forename: Giuliana
authors.initials: G
authors.lastname: Romeo
authors.forename: Julian
authors.initials: J
authors.lastname: Cooney
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D028861:Nuclear Pore Complex Proteins / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use*; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C085914:NUP214 protein, human; D028861:Nuclear Pore Complex Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016315:Proto-Oncogene Proteins c-abl